{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:32:06Z","timestamp":1793971926899,"version":"4.8.0"},"reference-count":276,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejphar.2026.179461","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:03:08Z","timestamp":1792738988000},"page":"179461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacological targeting of Fc receptor and FcRn pathways: Therapeutic antibody engineering in immune-mediated disorders"],"prefix":"10.1016","volume":"1038","author":[{"given":"Saeed","family":"Mobini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Chizari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Rismani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadjavad","family":"Sadrzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezoo","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0391-1769","authenticated-orcid":false,"given":"Ali","family":"Zarrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massoud","family":"Vosough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejphar.2026.179461_bib1","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.3390\/pharmaceutics15102402","article-title":"Fc-engineered therapeutic antibodies: recent advances and future directions","volume":"15","author":"Abdeldaim","year":"2023","journal-title":"Pharmaceutics"},{"issue":"15","key":"10.1016\/j.ejphar.2026.179461_bib2","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.2217\/fon.14.146","article-title":"Rituximab: modes of action, remaining dispute and future perspective","volume":"10","author":"Abulayha","year":"2014","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jsb.2016.02.001","article-title":"Structural characterization of GASDALIE Fc bound to the activating Fc receptor Fc\u03b3RIIIa","volume":"194","author":"Ahmed","year":"2016","journal-title":"J. Struct. Biol."},{"issue":"11","key":"10.1016\/j.ejphar.2026.179461_bib4","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.3390\/ijms25115793","article-title":"The association between genetics and response to treatment with biologics in patients with psoriasis, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases: a systematic review and meta-analysis","volume":"25","author":"Al-Sofi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.179461_bib5","doi-asserted-by":"crossref","first-page":"718","DOI":"10.54361\/ajmas.247337","article-title":"A review on autoimmune diseases: recent advances and future perspectives","author":"Albarbar","year":"2024","journal-title":"AlQalam Journal of Medical and Applied Sciences"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/imr.12337","article-title":"The era of the immunoglobulin A Fc receptor Fc\u03b1 RI; its function and potential as target in disease","volume":"268","author":"Aleyd","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejphar.2026.179461_bib7","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3389\/fimmu.2019.00464","article-title":"The human Fc\u03b3RII (CD32) family of leukocyte FcR in health and disease","volume":"10","author":"Anania","year":"2019","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179461_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005657","article-title":"Tumor-associated neutrophils and macrophages exacerbate antidrug IgG-mediated anaphylactic reaction against an immune checkpoint inhibitor","volume":"10","author":"Arai","year":"2022","journal-title":"J. ImmunoTher. Cancer"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1158\/1078-0432.CCR-25-0434","article-title":"Facts and hopes in harnessing macrophage-mediated antibody-dependent cellular phagocytosis for cancer immunotherapy","volume":"32","author":"Armero","year":"2026","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib10","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1172\/JCI129697","article-title":"The anti-IgE mAb omalizumab induces adverse reactions by engaging Fc\u03b3 receptors","volume":"130","author":"Balbino","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179461_bib11","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/icb.2016.121","article-title":"Role of Fc-Fc\u03b3R interactions in the antitumor activity of therapeutic antibodies","volume":"95","author":"Barnhart","year":"2017","journal-title":"Immunol. Cell Biol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179461_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001584","article-title":"Antitumor efficacy of combined CTLA4\/PD-1 blockade without intestinal inflammation is achieved by elimination of Fc\u03b3R interactions","volume":"8","author":"Bauch\u00e9","year":"2020","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.ejphar.2026.179461_bib13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3389\/fimmu.2019.00811","article-title":"Understanding Fc receptor involvement in inflammatory diseases: from mechanisms to new therapeutic tools","volume":"10","author":"Ben Mkaddem","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib14","series-title":"Fc Mediated Activity of Antibodies: Structural and Functional Diversity","first-page":"35","author":"Beneduce","year":"2019"},{"issue":"17","key":"10.1016\/j.ejphar.2026.179461_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cells12172130","article-title":"Inhibitory Fc-Gamma IIb receptor signaling induced by multivalent IgG-Fc is dependent on sialylation","volume":"12","author":"Beneduce","year":"2023","journal-title":"Cells"},{"issue":"710","key":"10.1016\/j.ejphar.2026.179461_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add1868","article-title":"Fc\u03b3RIIB expressed on CD8+ T cells limits responsiveness to PD-1 checkpoint inhibition in cancer","volume":"15","author":"Bennion","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2026.179461_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101392","article-title":"Peptide-YY3-36\/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic \u03b2-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries","volume":"55","author":"Boland","year":"2022","journal-title":"Mol. Metabol."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179461_bib18","first-page":"1098","article-title":"Extending human IgG half-life using structure-guided design","volume":"10","author":"Booth","year":"2018","journal-title":"mAbs"},{"issue":"23","key":"10.1016\/j.ejphar.2026.179461_bib19","doi-asserted-by":"crossref","first-page":"12943","DOI":"10.1073\/pnas.2004325117","article-title":"FcRn, but not Fc\u03b3Rs, drives maternal-fetal transplacental transport of human IgG antibodies","volume":"117","author":"Borghi","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179461_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/antib9020022","article-title":"Principles of N-linked glycosylation variations of IgG-based therapeutics: pharmacokinetic and functional considerations","volume":"9","author":"Boune","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.ejphar.2026.179461_bib21","series-title":"Myeloid Cells in Health and Disease: a Synthesis","first-page":"407","article-title":"The receptors role and on Myeloid function cells of Fc\u03b3","author":"Bournazos","year":"2020"},{"key":"10.1016\/j.ejphar.2026.179461_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1283120","article-title":"Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection","volume":"14","author":"Brady","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3389\/fimmu.2019.00704","article-title":"Potent Fc receptor signaling by IgA leads to superior killing of cancer cells by neutrophils compared to IgG","volume":"10","author":"Brandsma","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1029759","article-title":"Insulin-regulated aminopeptidase contributes to setting the intensity of FcR-mediated inflammation","volume":"13","author":"Bratti","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00553","article-title":"IgA and Fc\u03b1RI: pathological roles and therapeutic opportunities. Review","volume":"10","author":"Breedveld","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2505092","article-title":"Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies","volume":"17","author":"Brennan","year":"2025","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib27","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1038\/s41467-022-33764-1","article-title":"The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement","volume":"13","author":"Brinkhaus","year":"2022","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179461_bib28","article-title":"Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies","volume":"3","author":"Bruel","year":"2022","journal-title":"Cell Rep. Med."},{"issue":"9","key":"10.1016\/j.ejphar.2026.179461_bib29","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1084\/jem.20130573","article-title":"Activating Fc \u03b3 receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies","volume":"210","author":"Bulliard","year":"2013","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41531-025-01249-9","article-title":"Microglial low-affinity Fc\u03b3R mediates the phagocytic elimination of dopaminergic neurons in Parkinson's disease degeneration","volume":"12","author":"Casanova","year":"2026","journal-title":"npj Parkinson's Dis."},{"key":"10.1016\/j.ejphar.2026.179461_bib31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3389\/fimmu.2019.00805","article-title":"IgG and Fc\u03b3 receptors in intestinal immunity and inflammation","volume":"10","author":"Castro-Dopico","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.103016","article-title":"Fc receptors gone wrong: a comprehensive review of their roles in autoimmune and inflammatory diseases","volume":"21","author":"Chalayer","year":"2022","journal-title":"Autoimmun. Rev."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179461_bib34","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00262-024-03824-0","article-title":"The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy","volume":"73","author":"Chan","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.ejphar.2026.179461_bib33","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1586\/14787210.2015.1079127","article-title":"Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases","volume":"13","author":"Chan","year":"2015","journal-title":"Expert Rev. Anti-infect. Ther."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179461_bib35","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1158\/2159-8290.CD-24-0190","article-title":"Botensilimab, an Fc-Enhanced Anti\u2013CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy","volume":"14","author":"Chand","year":"2024","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179461_bib36","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/biomedicines12071597","article-title":"Anti-B-Cell-Activating factor (BAFF) therapy: a novel addition to autoimmune disease management and potential for immunomodulatory therapy in warm autoimmune Hemolytic anemia","volume":"12","author":"Cheekati","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2026.179461_bib39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jconrel.2020.08.021","article-title":"Antibody and antibody fragments for cancer immunotherapy","volume":"328","author":"Chen","year":"2020","journal-title":"J. Contr. Release"},{"issue":"9","key":"10.1016\/j.ejphar.2026.179461_bib37","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1177\/0961203315570686","article-title":"Measuring decreased serum IgG sialylation: a novel clinical biomarker of lupus","volume":"24","author":"Chen","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.ejphar.2026.179461_bib38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fimmu.2019.00292","article-title":"Fc\u03b3R-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib40","article-title":"An Fc-competent anti-human TIGIT blocking antibody ociperlimab (BGB-A1217) elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"issue":"22","key":"10.1016\/j.ejphar.2026.179461_bib43","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1158\/0008-5472.CAN-24-3174","article-title":"An Fc-Engineered glycomodified antibody supports proinflammatory activation of immune effector cells and restricts progression of breast cancer","volume":"85","author":"Chenoweth","year":"2025","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179461_bib42","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/imcb.12646","article-title":"Mutation of the TGN1412 anti\u2010CD28 monoclonal antibody lower Hinge confers specific Fc\u03b3RIIb binding and retention of super\u2010agonist activity","volume":"101","author":"Chenoweth","year":"2023","journal-title":"Immunol. Cell Biol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179461_bib41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/imcb.12326","article-title":"Harnessing the immune system via Fc\u03b3R function in immune therapy: a pathway to next\u2010gen mAbs","volume":"98","author":"Chenoweth","year":"2020","journal-title":"Immunol. Cell Biol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179461_bib44","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024380","article-title":"Glycoprotein acetyls: a novel inflammatory biomarker of early cardiovascular risk in the young","volume":"11","author":"Chiesa","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179461_bib45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/antib8040055","article-title":"Antibody structure and function: the basis for engineering therapeutics","volume":"8","author":"Chiu","year":"2019","journal-title":"Antibodies"},{"issue":"5","key":"10.1016\/j.ejphar.2026.179461_bib46","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1080\/19420862.2019.1605270","article-title":"An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans","volume":"11","author":"Chung","year":"2019","journal-title":"mAbs"},{"issue":"11","key":"10.1016\/j.ejphar.2026.179461_bib47","doi-asserted-by":"crossref","first-page":"e178351","DOI":"10.1172\/JCI178351","article-title":"IgG hexamers initiate complement-dependent acute lung injury","volume":"134","author":"Cleary","year":"2024","journal-title":"J. Clin. Investig."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179461_bib48","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.cell.2017.10.033","article-title":"A method for the acute and rapid degradation of endogenous proteins","volume":"171","author":"Clift","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ejphar.2026.179461_bib49","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/bjh.19858","article-title":"Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension","volume":"206","author":"Cooper","year":"2025","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.ejphar.2026.179461_bib50","doi-asserted-by":"crossref","first-page":"9771","DOI":"10.3390\/ijms24119771","article-title":"Mast cells in upper and lower airway diseases: sentinels in the front line","volume":"24","author":"Costanzo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib51","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2453515","article-title":"With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process","volume":"17","author":"Crescioli","year":"2025","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-Amyloid monoclonal antibodies for the treatment of Alzheimer's Disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejphar.2026.179461_bib53","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-319-07911-0_7","article-title":"Fc receptors as adaptive immunoreceptors","volume":"382","author":"Da\u00ebron","year":"2014","journal-title":"Fc Receptors"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib54","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/imr.13387","article-title":"The function of antibodies","volume":"328","author":"Da\u00ebron","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejphar.2026.179461_bib55","series-title":"The Impact of Antibody Biophysical Properties on Antigen Recognition and Fc Effector Functions","author":"Dahora","year":"2021"},{"key":"10.1016\/j.ejphar.2026.179461_bib56","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Therapeutic advances in neurological disorders"},{"key":"10.1016\/j.ejphar.2026.179461_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1304365","article-title":"Impact of structural modifications of IgG antibodies on effector functions","volume":"14","author":"Damelang","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib58","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-bioeng-082721-024500","article-title":"Improving antibody therapeutics by manipulating the Fc domain: immunological and structural considerations","volume":"24","author":"Delidakis","year":"2022","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.ejphar.2026.179461_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2022.10465","article-title":"The role of Fc gamma receptors in antibody-mediated rejection of kidney transplants","volume":"35","author":"Delpire","year":"2022","journal-title":"Transpl. Int."},{"issue":"10","key":"10.1016\/j.ejphar.2026.179461_bib60","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/ATVBAHA.124.319843","article-title":"Role of antibodies and their specificities in atherosclerotic cardiovascular disease","volume":"44","author":"Deroissart","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"24","key":"10.1016\/j.ejphar.2026.179461_bib61","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-Cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179461_bib62","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.cell.2015.04.016","article-title":"Differential Fc-Receptor engagement drives an anti-tumor vaccinal effect","volume":"161","author":"DiLillo","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ejphar.2026.179461_bib63","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/CJI.0000000000000465","article-title":"Enhancing the anti-tumor potency of a novel Siglec-15 antibody by engineering its Fc-mediated effector functions","volume":"46","author":"Ding","year":"2023","journal-title":"J. Immunother."},{"key":"10.1016\/j.ejphar.2026.179461_bib64","doi-asserted-by":"crossref","first-page":"12","DOI":"10.25259\/IJMIO_32_2025","article-title":"YTE-engineered antibodies: from neonatal Fc receptor binding mechanisms to next-generation therapeutics","volume":"11","author":"Dubey","year":"2026","journal-title":"International Journal of Molecular and Immuno Oncology"},{"issue":"6","key":"10.1016\/j.ejphar.2026.179461_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065724","article-title":"Harnessing Fc\/FcRn affinity data from patents with different machine learning methods","volume":"24","author":"Dumet","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179461_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230401","article-title":"Podocyte-specific knockout of the neonatal Fc receptor (FcRn) results in differential protection depending on the model of glomerulonephritis","volume":"15","author":"Dylewski","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib67","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2174\/1381612829666221025091827","article-title":"Recent knowledge and insights on the mechanisms of immediate hypersensitivity and anaphylaxis: IgE\/FcRI-and Non-IgE\/FcRI-Dependent anaphylaxis","volume":"29","author":"Ebo","year":"2023","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib68","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/imr.13393","article-title":"Fc-Fc\u03b3R interactions during infections: from neutralizing antibodies to antibody-dependent enhancement","volume":"328","author":"Edgar","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejphar.2026.179461_bib69","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.ai.2020.10.003","article-title":"IgE and mast cells: the endogenous adjuvant","volume":"148","author":"El Ansari","year":"2020","journal-title":"Adv. Immunol."},{"issue":"23","key":"10.1016\/j.ejphar.2026.179461_bib70","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.3390\/jcm13237243","article-title":"Alpha-Synuclein and Microglia in parkinson's disease: from pathogenesis to therapeutic prospects","volume":"13","author":"Eo","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2026.179461_bib71","series-title":"Systemic Lupus Erythematosus","first-page":"179","article-title":"Fc\u03b3 receptors in autoimmunity and end-organ damage","author":"Ernandez","year":"2021"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib72","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/imr.12368","article-title":"Fc\u03b3 RIIB and autoimmunity","volume":"269","author":"Esp\u00e9li","year":"2016","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/antib15010017","article-title":"Microsecond dynamics of Fc-CD16a recognition: impact of mutations, core fucosylation, and Fc asymmetry","volume":"15","author":"Estaran","year":"2026","journal-title":"Antibodies"},{"issue":"4","key":"10.1016\/j.ejphar.2026.179461_bib74","doi-asserted-by":"crossref","first-page":"363","DOI":"10.5114\/ceji.2017.72817","article-title":"Fc\u03b3RIIa defunctioning polymorphism in paediatric patients with renal allograft","volume":"42","author":"Fadel","year":"2017","journal-title":"Cent. Eur. J. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107718","article-title":"Emerging mechanisms contributing to mast cell-mediated pathophysiology with therapeutic implications","volume":"220","author":"Falduto","year":"2021","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2026.179461_bib76","series-title":"Single Domain antibody-scFv Conjugate Targeting Amyloid \u0392 and Tfr Penetrates the blood\u2013brain Barrier and Interacts with Amyloid \u0392","author":"Faresj\u00f6","year":"2024"},{"key":"10.1016\/j.ejphar.2026.179461_bib77","series-title":"New Approaches to Treating Cancer Using immune-checkpoint Blockade","author":"Fellermeyer","year":"2023"},{"issue":"7","key":"10.1016\/j.ejphar.2026.179461_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103612","article-title":"Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases","volume":"28","author":"Felten","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2026.179461_bib79","first-page":"1","article-title":"New immune cell engagers for cancer immunotherapy","author":"Fenis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"31","key":"10.1016\/j.ejphar.2026.179461_bib80","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1073\/pnas.1108455108","article-title":"Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose","volume":"108","author":"Ferrara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"18","key":"10.1016\/j.ejphar.2026.179461_bib81","doi-asserted-by":"crossref","first-page":"E2385","DOI":"10.1073\/pnas.1505292112","article-title":"Protection in antibody-and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs","volume":"112","author":"Fiebiger","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.179461_bib82","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fimmu.2020.00496","article-title":"Engineering of Fc multimers as a protein therapy for autoimmune disease","volume":"11","author":"Fitzpatrick","year":"2020","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.ejphar.2026.179461_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115177","article-title":"The role of inflammation in neurodegenerative diseases: Parkinson's Disease, Alzheimer's Disease, and multiple sclerosis","volume":"26","author":"Fo\u0142ta","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib84","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/imr.13401","article-title":"Fc gamma receptors: their evolution, genomic architecture, genetic variation, and impact on human disease","volume":"328","author":"Frampton","year":"2024","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib85","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00915-2020","article-title":"Alveolar macrophage transcriptomic profiling in COPD shows major lipid metabolism changes","volume":"7","author":"Fujii","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.ejphar.2026.179461_bib86","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fnins.2014.00235","article-title":"New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease","volume":"8","author":"Fuller","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejphar.2026.179461_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2024.1389669","article-title":"Allergen-specific IgA and IgG antibodies as inhibitors of mast cell function in food allergy","volume":"5","author":"Furiness","year":"2024","journal-title":"Frontiers in Allergy"},{"issue":"7","key":"10.1016\/j.ejphar.2026.179461_bib88","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.it.2014.05.002","article-title":"Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies","volume":"35","author":"Furness","year":"2014","journal-title":"Trends Immunol."},{"issue":"754","key":"10.1016\/j.ejphar.2026.179461_bib89","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj5958","article-title":"Nasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice","volume":"16","author":"Gaikwad","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"17","key":"10.1016\/j.ejphar.2026.179461_bib90","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib91","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41568-023-00637-8","article-title":"Fc\u03b3 receptors and immunomodulatory antibodies in cancer","volume":"24","author":"Galvez-Cancino","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib92","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s11033-024-09877-9","article-title":"Current development of Fc gamma receptors (Fc\u03b3Rs) in diagnostics: a review","volume":"51","author":"Gan","year":"2024","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med."},{"issue":"15","key":"10.1016\/j.ejphar.2026.179461_bib94","doi-asserted-by":"crossref","first-page":"8656","DOI":"10.3390\/ijms23158656","article-title":"Activation markers on B and T Cells and immune checkpoints in autoimmune rheumatic diseases","volume":"23","author":"Gerasimova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.179461_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-018-0245-9","article-title":"Tau oligomers mediate \u03b1-synuclein toxicity and can be targeted by immunotherapy","volume":"13","author":"Gerson","year":"2018","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib96","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/imr.12336","article-title":"Of ITIMs, ITAMs, and ITAMis: revisiting immunoglobulin Fc receptor signaling","volume":"268","author":"Getahun","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejphar.2026.179461_bib97","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jaut.2016.09.009","article-title":"In vivo effector functions of high-affinity mouse IgG receptor Fc\u03b3RI in disease and therapy models","volume":"80","author":"Gillis","year":"2017","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib98","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40259-025-00708-2","article-title":"Targeting the neonatal Fc receptor in autoimmune diseases: Pipeline and progress","volume":"39","author":"Gj\u00f8lberg","year":"2025","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejphar.2026.179461_bib99","first-page":"1","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","author":"Goebeler","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.ejphar.2026.179461_bib100","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.3390\/ijms22168947","article-title":"The role of Fc receptors on the effectiveness of therapeutic monoclonal antibodies","volume":"22","author":"Gogesch","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.179461_bib101","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3389\/fimmu.2019.00175","article-title":"Current strategies to inhibit high affinity Fc\u03b5RI-mediated signaling for the treatment of allergic disease","volume":"10","author":"Gomez","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib102","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/imm.12541","article-title":"Contribution of Fc\u03b3 receptors to human respiratory syncytial virus pathogenesis and the impairment of T-cell activation by dendritic cells","volume":"147","author":"G\u00f3mez","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.ejphar.2026.179461_bib103","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/82_2019_150","article-title":"Role of Fc\u03b3Rs in antibody-based cancer therapy","author":"Graziano","year":"2019","journal-title":"Fc Mediated Activity of Antibodies: Structural and Functional Diversity"},{"issue":"10","key":"10.1016\/j.ejphar.2026.179461_bib104","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1021\/acs.bioconjchem.5c00379","article-title":"Antibody engineering for receptor-mediated transcytosis across the blood-brain barrier","volume":"36","author":"Guo","year":"2025","journal-title":"Bioconjug. Chem."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179461_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0284636","article-title":"Knockout of the neonatal Fc receptor alters immune complex trafficking and lysosomal function in cultured podocytes","volume":"18","author":"Haddad","year":"2023","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ejphar.2026.179461_bib106","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1042\/BCJ20253380","article-title":"Effect of ADCC-enhancing mutations on N-glycan profiles of human IgG1 antibodies","volume":"483","author":"Han","year":"2026","journal-title":"Biochem. J."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179461_bib107","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.ejphar.2026.179461_bib108","doi-asserted-by":"crossref","DOI":"10.31083\/j.jin2311203","article-title":"The role of microglia and astrocytes in the pathomechanism of neuroinflammation in Parkinson's disease-focus on alpha-synuclein","volume":"23","author":"Harackiewicz","year":"2024","journal-title":"J. Integr. Neurosci."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179461_bib109","doi-asserted-by":"crossref","DOI":"10.1172\/JCI134680","article-title":"Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity","volume":"131","author":"Heemskerk","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib110","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.ejphar.2026.179461_bib111","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol. Cancer Therapeut."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib112","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s42003-024-06633-4","article-title":"Allosteric inhibition of IgE-Fc\u03b5RI interactions by simultaneous targeting of IgE F(ab')2 epitopes","volume":"7","author":"Hirano","year":"2024","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib113","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s10928-024-09952-5","article-title":"Translational population target binding model for the anti-FcRn fragment antibody efgartigimod","volume":"52","author":"Hoefman","year":"2024","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib114","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1395127","article-title":"Antibody structure and engineering considerations for the design and function of antibody Drug Conjugates (ADCs)","volume":"7","author":"Hoffmann","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib115","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltac011","article-title":"Targeting the high affinity receptor, Fc\u03b3RI, in autoimmune disease, neuropathy, and cancer","volume":"2","author":"Holtrop","year":"2022","journal-title":"Immunother Adv"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib116","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1021\/acsomega.9b00029","article-title":"Liposomal fc domain conjugated to a cancer vaccine enhances both humoral and cellular immunity","volume":"4","author":"Hossain","year":"2019","journal-title":"ACS Omega"},{"issue":"8","key":"10.1016\/j.ejphar.2026.179461_bib117","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1074\/mcp.M900540-MCP200","article-title":"Post-translational modifications differentially affect IgG1 conformation and receptor binding","volume":"9","author":"Houde","year":"2010","journal-title":"Mol. Cell. Proteomics"},{"issue":"2","key":"10.1016\/j.ejphar.2026.179461_bib118","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13020299","article-title":"Anti-drug antibody response to therapeutic antibodies and potential mitigation strategies","volume":"13","author":"Howard","year":"2025","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.ejphar.2026.179461_bib119","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2256904","article-title":"Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer","volume":"19","author":"Huan","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib120","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/imm.12609","article-title":"Anti\u2010CD 25 monoclonal antibody Fc variants differentially impact regulatory T cells and immune homeostasis","volume":"148","author":"Huss","year":"2016","journal-title":"Immunology"},{"issue":"7","key":"10.1016\/j.ejphar.2026.179461_bib121","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.cell.2016.11.039","article-title":"Dissecting immune circuits by linking CRISPR-pooled screens with single-cell RNA-seq","volume":"167","author":"Jaitin","year":"2016","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib122","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1620\/tjem.236.185","article-title":"Fc\u03b3RIIB gene polymorphisms are associated with disease risk and clinical manifestations of systemic lupus erythematosus in Koreans","volume":"236","author":"Jeon","year":"2015","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.ejphar.2026.179461_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.685865","article-title":"Responses of mast cells to pathogens: beneficial and detrimental roles","volume":"12","author":"Jim\u00e9nez","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2019.101665","article-title":"Targeting the transferrin receptor for brain drug delivery","volume":"181","author":"Johnsen","year":"2019","journal-title":"Prog. Neurobiol."},{"issue":"500","key":"10.1016\/j.ejphar.2026.179461_bib125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat1479","article-title":"An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis","volume":"11","author":"J\u00f6nsson","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2026.179461_bib126","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3389\/fimmu.2020.01393","article-title":"Fc gamma receptors and their role in antigen uptake, presentation, and T cell activation","volume":"11","author":"Junker","year":"2020","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.ejphar.2026.179461_bib127","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.4049\/jimmunol.170.8.4318","article-title":"Essential role of Fc\u03b3 receptors in anti-type II collagen antibody-induced arthritis","volume":"170","author":"Kagari","year":"2003","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179461_bib128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/intimm\/dxx041","article-title":"Polymorphisms of immunoglobulin receptors and the effects on clinical outcome in cancer immunotherapy and other immune diseases: a general review","volume":"29","author":"Kaifu","year":"2017","journal-title":"Int. Immunol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179461_bib130","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jaci.2023.03.027","article-title":"IgG:Fc\u03b3RIIb signals block effector programs of IgE:Fc\u03b5RI-activated mast cells but spare survival pathways","volume":"152","author":"Kanagaratham","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.603050","article-title":"IgE and IgG antibodies as regulators of mast cell and basophil functions in food allergy","volume":"11","author":"Kanagaratham","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179461_bib131","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.4049\/jimmunol.180.4.2669","article-title":"Inhibitory ITAM signaling by Fc\u03b1RI-FcR\u03b3 chain controls multiple activating responses and prevents renal Inflammation1","volume":"180","author":"Kanamaru","year":"2008","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.ejphar.2026.179461_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0345-9","article-title":"Boosting therapeutic potency of antibodies by taming Fc domain functions","volume":"51","author":"Kang","year":"2019","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib133","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/abt\/tbad027","article-title":"Next generation of multispecific antibody engineering","volume":"7","author":"Keri","year":"2024","journal-title":"Antibody Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib134","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41467-025-57108-x","article-title":"Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution","volume":"16","author":"Khoury","year":"2025","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.ejphar.2026.179461_bib135","doi-asserted-by":"crossref","first-page":"9489","DOI":"10.3390\/ijms22179489","article-title":"Fc receptor variants and disease: a crucial factor to consider in the antibody therapeutics in clinic","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl. l","key":"10.1016\/j.ejphar.2026.179461_bib136","article-title":"PB2305: efgartigimod: clinical development of a novel FCRN antagonist in the treatment of autoimmune diseases","volume":"6","author":"Knoebl","year":"2022","journal-title":"HemaSphere"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib137","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1158\/2326-6066.CIR-23-0389","article-title":"Fc\u03b3RIIB is an immune checkpoint limiting the activity of treg-targeting antibodies in the tumor microenvironment","volume":"12","author":"Knorr","year":"2024","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179461_bib138","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40259-021-00471-0","article-title":"Recent achievements and challenges in prolonging the serum half-lives of therapeutic IgG antibodies through Fc engineering","volume":"35","author":"Ko","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejphar.2026.179461_bib139","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3389\/fimmu.2019.00544","article-title":"Inside-out control of Fc-receptors","volume":"10","author":"Koenderman","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib140","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fimmu.2019.00190","article-title":"Identification of soluble mediators in IgG-mediated anaphylaxis via Fc\u03b3 receptor: a meta-analysis","volume":"10","author":"Kow","year":"2019","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.ejphar.2026.179461_bib141","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1158\/1078-0432.CCR-17-3786","article-title":"Mechanistic insights of an immunological adverse event induced by an anti-KIT antibody drug conjugate and mitigation strategies","volume":"24","author":"L'Italien","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.179461_bib142","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188497","article-title":"Fc receptors act as innate immune receptors during infection?","volume":"14","author":"Laassili","year":"2023","journal-title":"Front. Immunol."},{"issue":"13","key":"10.1016\/j.ejphar.2026.179461_bib143","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/1878-0261.13166","article-title":"Fc\u03b3RIIIa receptor interacts with androgen receptor and PIP5K1\u03b1 to promote growth and metastasis of prostate cancer","volume":"16","author":"Larsson","year":"2022","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib144","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.13071","article-title":"Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35\/98)","volume":"168","author":"Lee","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"6_Suppl. ment","key":"10.1016\/j.ejphar.2026.179461_bib146","article-title":"CTN001, a first Twin Fc-immune cell engager, with a superior potency against Her2+ and Her2-low cancers by engaging multiple Fc-mediated mechanisms","volume":"84","author":"Lee","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.179461_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118973","article-title":"Targeting eosinophils in respiratory diseases: biological axis, emerging therapeutics and treatment modalities","volume":"267","author":"Lee","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2026.179461_bib147","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02450","article-title":"Editorial: antibody Fc engineering: towards better therapeutics. Editorial","volume":"9","author":"Lei","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib148","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/14728222.2014.877891","article-title":"Targeting the Fc receptor in autoimmune disease","volume":"18","author":"Li","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib149","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12016-022-08955-9","article-title":"New mechanistic advances in Fc\u03b5RI-mast cell\u2013mediated allergic signaling","volume":"63","author":"Li","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"8","key":"10.1016\/j.ejphar.2026.179461_bib150","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/abbs\/gmu044","article-title":"The anorexic effect of Ex4\/Fc through GLP-1 receptor activation in high-fat diet fed mice","volume":"46","author":"Liu","year":"2014","journal-title":"Acta Biochim. Biophys. Sin."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179461_bib151","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/antib9040064","article-title":"Fc-engineering for modulated effector functions\u2014improving antibodies for cancer treatment","volume":"9","author":"Liu","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.ejphar.2026.179461_bib152","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1679092","article-title":"Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives","volume":"16","author":"Lopatnikova","year":"2025","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179461_bib153","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.463","article-title":"Fc\u03b3 receptor activation mediates vascular inflammation and abdominal aortic aneurysm development","volume":"11","author":"Lopez-Sanz","year":"2021","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib154","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41598-019-57184-2","article-title":"Characterization of IgG1 Fc deamidation at asparagine 325 and its impact on antibody-dependent cell-mediated cytotoxicity and Fc\u03b3RIIIa binding","volume":"10","author":"Lu","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib155","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41698-025-01159-2","article-title":"Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology","volume":"9","author":"Lu","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.ejphar.2026.179461_bib156","series-title":"Reference Module in Biomedical Sciences","article-title":"Fc receptors in immune responses","author":"Mancardi","year":"2014"},{"issue":"12","key":"10.1016\/j.ejphar.2026.179461_bib158","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13122975","article-title":"Efgartigimod for generalized Myasthenia gravis and beyond: a narrative review of its pharmacological profile, clinical utility, and expanding applications","volume":"13","author":"Mansour","year":"2025","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib157","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/s-0036-1579633","article-title":"Polymorphisms of immunoglobulin G Fc receptors in pediatric Guillain\u2013Barr\u00e9 syndrome","volume":"47","author":"Mansour","year":"2016","journal-title":"Neuropediatrics"},{"issue":"13_Suppl. ment","key":"10.1016\/j.ejphar.2026.179461_bib159","article-title":"A novel Fc\u03b3RIIB-blocking antibody to enhance Fc\u03b3R-dependent antitumor immunity","volume":"81","author":"M\u00e5rtensson","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.179461_bib160","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.926289","article-title":"Relevance of Fc gamma receptor polymorphisms in cancer therapy with monoclonal antibodies","volume":"12","author":"Mata-Molanes","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib161","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/all.15933","article-title":"Biomarkers of immediate drug hypersensitivity","volume":"79","author":"Mayorga","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.ejphar.2026.179461_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2024.148607","article-title":"Emerging trends and therapeutic applications of monoclonal antibodies","volume":"925","author":"Mekala","year":"2024","journal-title":"Gene"},{"key":"10.1016\/j.ejphar.2026.179461_bib163","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1032379","article-title":"Basophils control T cell priming through soluble mediators rather than antigen presentation","volume":"13","author":"M\u00f6bs","year":"2023","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179461_bib164","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/CJI.0000000000000464","article-title":"A novel Fc-Engineered Anti-HER2 bispecific antibody with enhanced antitumor activity","volume":"46","author":"Mohammadi","year":"2023","journal-title":"J. Immunother."},{"key":"10.1016\/j.ejphar.2026.179461_bib165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.728322","article-title":"The dual targeting of FcRn and Fc\u03b3Rs via monomeric fc fragments results in strong inhibition of IgG-dependent autoimmune pathologies","volume":"12","author":"Monnet","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib166","series-title":"Fc: Fc Gamma Receptor Interactions in anti-PD-1 Monoclonal Antibody Therapy and their Role in Anti-tumour Immunity Against Neuroblastoma","author":"Moreno Vicente","year":"2020"},{"issue":"12","key":"10.1016\/j.ejphar.2026.179461_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e08518","article-title":"Immune gene network of neurological diseases: multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD)","volume":"7","author":"Mukherjee","year":"2021","journal-title":"Heliyon"},{"issue":"4","key":"10.1016\/j.ejphar.2026.179461_bib168","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153620","article-title":"Immune complex-induced, nitric oxide-mediated vascular endothelial cell death by phagocytes is prevented with decoy fc\u03b3receptors","volume":"11","author":"Mula","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib169","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003171","article-title":"Role of Fc\u03b3 receptors in HER2-targeted breast cancer therapy","volume":"10","author":"Musolino","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.ejphar.2026.179461_bib170","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040622","article-title":"Fc\u03b5RI: a master regulator of mast cell functions","volume":"11","author":"Nagata","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib171","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13311-021-01175-7","article-title":"Neonatal Fc receptor-targeted therapies in neurology","volume":"19","author":"Nelke","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.ejphar.2026.179461_bib172","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib173","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/cei.13371","article-title":"Dysregulated Fc\u03b3 receptor IIa-induced cytokine production in dendritic cells of lupus nephritis patients","volume":"199","author":"Newling","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib174","series-title":"Design, Engineering, and Characterization of a Bispecific Killer Cell Engager with High Affinity and Specificity Toward CD16a Receptor on Natural Killer Cells for Cancer Immunotherapy","author":"Nikkhoi","year":"2023"},{"key":"10.1016\/j.ejphar.2026.179461_bib175","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.immunol.26.021607.090232","article-title":"Anti-inflammatory actions of intravenous immunoglobulin","volume":"26","author":"Nimmerjahn","year":"2008","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179461_bib176","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/brain\/awx052","article-title":"Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model","volume":"140","author":"Nisbet","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2026.179461_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108783","article-title":"Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy","volume":"109","author":"Niu","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"365","key":"10.1016\/j.ejphar.2026.179461_bib178","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9418","article-title":"Elucidating the interplay between IgG-Fc valency and Fc\u03b3R activation for the design of immune complex inhibitors","volume":"8","author":"Ortiz","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179461_bib179","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.ccell.2023.10.007","article-title":"The antitumor activities of anti-CD47 antibodies require Fc-Fc\u03b3R interactions","volume":"41","author":"Osorio","year":"2023","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib180","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.11.041","article-title":"Engineered sialylation of pathogenic antibodies in vivo attenuates autoimmune disease","volume":"172","author":"Pagan","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib181","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nri.2017.76","article-title":"Single-cell RNA sequencing to explore immune cell heterogeneity","volume":"18","author":"Papalexi","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib182","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc receptor in human immunity: function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib183","first-page":"1","article-title":"Neurodegenerative disorders of alzheimer, parkinsonism, amyotrophic lateral sclerosis and multiple sclerosis: an early diagnostic approach for precision treatment","author":"Pathak","year":"2021","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.ejphar.2026.179461_bib184","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.3389\/fimmu.2019.01208","article-title":"FCGR3A and FCGR2A genotypes differentially impact allograft rejection and patients' survival after lung transplant","volume":"10","author":"Paul","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib185","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1211332","article-title":"Identification of the biological processes, immune cell landscape, and hub genes shared by acute anaphylaxis and ST-segment elevation myocardial infarction","volume":"14","author":"Peng","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib187","doi-asserted-by":"crossref","DOI":"10.1038\/srep33198","article-title":"Effects of allergic diseases and age on the composition of serum IgG glycome in children","volume":"6","author":"Pezer","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib188","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3233\/JAD-210417","article-title":"Blockage of Fc gamma receptors alleviates neuronal and microglial toxicity induced by palmitic acid","volume":"82","author":"Phitthayaphong","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2026.179461_bib189","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2023.1117611","article-title":"On the complexity of IgE: the role of structural flexibility and glycosylation for binding its receptors","volume":"4","author":"Plattner","year":"2023","journal-title":"Frontiers in allergy"},{"key":"10.1016\/j.ejphar.2026.179461_bib190","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","article-title":"Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy","volume":"55","author":"Pl\u00fcckthun","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179461_bib191","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.3390\/ijms24065925","article-title":"Immune regulatory functions of macrophages and microglia in central nervous system diseases","volume":"24","author":"Poppell","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"38","key":"10.1016\/j.ejphar.2026.179461_bib192","doi-asserted-by":"crossref","first-page":"E8882","DOI":"10.1073\/pnas.1807478115","article-title":"Fc\u03b1RI binding at the IgA1 C(H)2-C(H)3 interface induces long-range conformational changes that are transmitted to the Hinge region","volume":"115","author":"Posgai","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2026.179461_bib193","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/9783527699124.ch3","article-title":"Human antibody structure and function","volume":"1","author":"Prabakaran","year":"2017","journal-title":"Protein Therapeutics"},{"issue":"7","key":"10.1016\/j.ejphar.2026.179461_bib194","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib195","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/imr.12370","article-title":"The platelet Fc receptor, Fc\u03b3RIIa","volume":"268","author":"Qiao","year":"2015","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib196","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17255-8","article-title":"Multivalent Fc \u03b3-receptor engagement by a hexameric Fc-fusion protein triggers Fc \u03b3-receptor internalisation and modulation of Fc \u03b3-receptor functions","volume":"7","author":"Qureshi","year":"2017","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.ejphar.2026.179461_bib197","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.3390\/molecules27103194","article-title":"Neuroinflammatory markers: key indicators in the pathology of neurodegenerative diseases","volume":"27","author":"Rauf","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2026.179461_bib198","series-title":"Molecular Biology of B Cells","first-page":"129","article-title":"Fc receptors","author":"Ravetch","year":"2024"},{"issue":"2","key":"10.1016\/j.ejphar.2026.179461_bib199","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2017.06.003","article-title":"The pathophysiology of anaphylaxis","volume":"140","author":"Reber","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib200","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jaut.2015.05.004","article-title":"Allelic and copy-number variations of Fc\u03b3Rs affect granulocyte function and susceptibility for autoimmune blistering diseases","volume":"61","author":"Recke","year":"2015","journal-title":"J. Autoimmun."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179461_bib201","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/glycob\/cwv065","article-title":"Fc glycans of therapeutic antibodies as critical quality attributes","volume":"25","author":"Reusch","year":"2015","journal-title":"Glycobiology"},{"key":"10.1016\/j.ejphar.2026.179461_bib202","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1401471","article-title":"TRIM21 and Fc-engineered antibodies: decoding its complex antibody binding mode with implications for viral neutralization","volume":"15","author":"Reusch","year":"2024","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179461_bib203","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults","volume":"57","author":"Robbie","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179461_bib204","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/brain\/awab465","article-title":"Next-generation antibody-based therapies in neurology","volume":"145","author":"Ruck","year":"2022","journal-title":"Brain"},{"issue":"18","key":"10.1016\/j.ejphar.2026.179461_bib205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810017","article-title":"Crosstalk between metabolic disorders and immune cells","volume":"22","author":"Saitoh","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.179461_bib206","series-title":"Immunology: Overview and Laboratory Manual","author":"Sam-Yellowe","year":"2021"},{"issue":"4","key":"10.1016\/j.ejphar.2026.179461_bib207","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/imm.13743","article-title":"Engineered polyspecific antibodies: a new frontier in the field of immunotherapeutics","volume":"171","author":"Sandeep","year":"2024","journal-title":"Immunology"},{"issue":"1_Suppl. ment","key":"10.1016\/j.ejphar.2026.179461_bib208","article-title":"In vivo PK\/PD assessment of invisibilized IgG cleaving protease for chronic treatment of autoimmune diseases","volume":"210","author":"Sanmarco","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib209","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3389\/fimmu.2019.01296","article-title":"Conceptual approaches to modulating antibody effector functions and circulation half-life","volume":"10","author":"Saunders","year":"2019","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.ejphar.2026.179461_bib210","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng. Des. Sel."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179461_bib211","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40495-023-00327-x","article-title":"Pharmacokinetics and pharmacodynamics of neonatal Fc receptor (FcRn)-Targeting therapeutic proteins: a systemic review","volume":"9","author":"Sharma","year":"2023","journal-title":"Current Pharmacology Reports"},{"issue":"7","key":"10.1016\/j.ejphar.2026.179461_bib212","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.cell.2018.10.024","article-title":"Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function","volume":"175","author":"Shifrut","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib213","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2026.2657099","article-title":"Impact of afucosylation strategy on antibody function: a comparative study of glycoengineered anti-CD20 antibodies Obinutuzumab and Obinutuzumab beta","volume":"18","author":"Shuang","year":"2026","journal-title":"mAbs"},{"issue":"8","key":"10.1016\/j.ejphar.2026.179461_bib214","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/pro.173","article-title":"Effect of protein structure on deamidation rate in the Fc fragment of an IgG1 monoclonal antibody","volume":"18","author":"Sinha","year":"2009","journal-title":"Protein Sci."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179461_bib215","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nri2762","article-title":"FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications","volume":"10","author":"Smith","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib216","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10753-017-0661-y","article-title":"The pyrazole derivative BTP2 attenuates IgG immune complex-induced inflammation","volume":"41","author":"Sogkas","year":"2018","journal-title":"Inflammation"},{"issue":"8","key":"10.1016\/j.ejphar.2026.179461_bib217","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.4049\/jimmunol.1701171","article-title":"rIgG1 Fc hexamer inhibits antibody-mediated autoimmune disease via effects on complement and Fc\u03b3Rs","volume":"200","author":"Spirig","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-017-1050-z","article-title":"Fc gamma receptors are expressed in the developing rat brain and activate downstream signaling molecules upon cross-linking with immune complex","volume":"15","author":"Stamou","year":"2018","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib219","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40425-014-0029-x","article-title":"The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer","volume":"2","author":"Stewart","year":"2014","journal-title":"J. ImmunoTher. Cancer"},{"issue":"7","key":"10.1016\/j.ejphar.2026.179461_bib220","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.joca.2015.02.019","article-title":"Fc-gamma receptors are not involved in cartilage damage during experimental osteoarthritis","volume":"23","author":"Stock","year":"2015","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.ejphar.2026.179461_bib221","article-title":"IgG in the control of Fc\u03b5RI activation: a battle on multiple fronts","volume":"14","author":"Storni","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib222","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41392-022-01273-8","article-title":"Fc effector of anti-A\u03b2 antibody induces synapse loss and cognitive deficits in Alzheimer's disease-like mouse model","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib223","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/antib8010019","article-title":"IgE antibodies: from structure to function and clinical translation","volume":"8","author":"Sutton","year":"2019","journal-title":"Antibodies"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib224","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1923366","article-title":"The influence of antibody engineering on Fc conformation and Fc receptor binding properties: analysis of FcRn-binding engineered antibodies and an Fc fusion protein","volume":"13","author":"Suzuki","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.ejphar.2026.179461_bib225","series-title":"IgG4 can Induce an M2-like Phenotype in Human monocyte-derived Macrophages Through Fc\u03b3ri","first-page":"1377","author":"Swisher","year":"2014"},{"issue":"8","key":"10.1016\/j.ejphar.2026.179461_bib226","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nri856","article-title":"Roles of Fc receptors in autoimmunity","volume":"2","author":"Takai","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib227","first-page":"144","article-title":"Transferrin receptor engagement by polymeric IgA1 induces receptor expression and mesangial cell proliferation: role in IgA nephropathy","volume":"157","author":"Tamouza","year":"2007","journal-title":"Contrib. Nephrol."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179461_bib229","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.2337\/db15-1605","article-title":"Endothelial Fc\u03b3 receptor IIB activation blunts insulin delivery to skeletal muscle to cause insulin resistance in mice","volume":"65","author":"Tanigaki","year":"2016","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.ejphar.2026.179461_bib228","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1161\/CIRCRESAHA.116.302795","article-title":"Fc\u03b3 receptors and ligands and cardiovascular disease","volume":"116","author":"Tanigaki","year":"2015","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179461_bib230","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004278","article-title":"Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study","volume":"10","author":"Taylor","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.ejphar.2026.179461_bib231","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3389\/fimmu.2019.00481","article-title":"Targeting the antibody checkpoints to enhance cancer immunotherapy\u2013focus on Fc\u03b3RIIB","volume":"10","author":"Teige","year":"2019","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179461_bib232","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/ni.3731","article-title":"The multiple pathways to autoimmunity","volume":"18","author":"Theofilopoulos","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejphar.2026.179461_bib233","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.933468","article-title":"Role of B-cell in the pathogenesis of systemic sclerosis","volume":"13","author":"Thoreau","year":"2022","journal-title":"Front. Immunol."},{"issue":"21","key":"10.1016\/j.ejphar.2026.179461_bib234","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.3390\/cancers13215446","article-title":"Enhancement of NK cell antitumor effector functions using a bispecific single domain antibody targeting CD16 and the epidermal growth factor receptor","volume":"13","author":"Toffoli","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib235","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/s42003-025-08252-z","article-title":"Identification of a direct interaction between the Fab domains of IgG antibodies and human FcRn upon IgG-FcRn complex formation","volume":"8","author":"Trabjerg","year":"2025","journal-title":"Commun. Biol."},{"issue":"8","key":"10.1016\/j.ejphar.2026.179461_bib236","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/imcb.12570","article-title":"Presence and possible impact of Fc\u03b3 receptors on resident kidney cells in health and disease","volume":"100","author":"Typiak","year":"2022","journal-title":"Immunol. Cell Biol."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179461_bib237","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/biology12121501","article-title":"The B cell response and formation of Allergenic and anti-allergenic antibodies in food allergy","volume":"12","author":"Udoye","year":"2023","journal-title":"Biology"},{"issue":"10","key":"10.1016\/j.ejphar.2026.179461_bib238","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Investig."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179461_bib239","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/oby.21309","article-title":"FcR\u03b3-chain deficiency reduces the development of diet-induced obesity","volume":"23","author":"van Beek","year":"2015","journal-title":"Obesity"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib240","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/imr.13394","article-title":"Enhancing fc\u2010mediated effector functions of monoclonal antibodies: the example of HexaBodies","volume":"328","author":"van der Horst","year":"2024","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.ejphar.2026.179461_bib241","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.3390\/cancers12103041","article-title":"Fc-engineered antibodies with enhanced Fc-effector function for the treatment of B-cell malignancies","volume":"12","author":"van der Horst","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.ejphar.2026.179461_bib242","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00259-023-06177-5","article-title":"FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging committee perspective","volume":"50","author":"Verger","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejphar.2026.179461_bib243","doi-asserted-by":"crossref","DOI":"10.1111\/eci.12948","article-title":"Immune complex\u2010induced neutrophil functions: a focus on cell death","volume":"48","author":"Vermeren","year":"2018","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2026.179461_bib244","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179461_bib245","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000527481","article-title":"Allergy, anaphylaxis, and nonallergic hypersensitivity: Ige, mast cells, and beyond","volume":"31","author":"Vitte","year":"2022","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.ejphar.2026.179461_bib246","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-biochem-062917-012911","article-title":"Glycoengineering of antibodies for modulating functions","volume":"88","author":"Wang","year":"2019","journal-title":"Annu. Rev. Biochem."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib247","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s12264-022-00957-z","article-title":"Association of glial activation and \u03b1-synuclein pathology in Parkinson's disease","volume":"39","author":"Wang","year":"2023","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.ejphar.2026.179461_bib248","article-title":"Precision engineering of antibodies: a review of modification and design in the Fab region","author":"Wang","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib250","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2480666","article-title":"Maximizing activity and selectivity of antibody-mediated effector functions using antibody mixtures","volume":"17","author":"Wang","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.ejphar.2026.179461_bib249","doi-asserted-by":"crossref","DOI":"10.1093\/abt\/tbae017","article-title":"Fc engineering by monoclonal Mammalian cell display for improved affinity and selectivity towards Fc\u03b3Rs","author":"Wang","year":"2024","journal-title":"Antibody Ther."},{"issue":"10","key":"10.1016\/j.ejphar.2026.179461_bib251","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.tips.2018.07.007","article-title":"Targeting FcRn to generate antibody-based therapeutics","volume":"39","author":"Ward","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib252","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202249947","article-title":"Therapeutic tactics for targeting B lymphocytes in autoimmunity and cancer","volume":"54","author":"Wemlinger","year":"2024","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179461_bib253","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.4049\/jimmunol.1101135","article-title":"Interaction with Fc\u03b3RIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody","volume":"187","author":"White","year":"2011","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179461_bib254","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260954","article-title":"Fc-engineered antibodies with immune effector functions completely abolished","volume":"16","author":"Wilkinson","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ejphar.2026.179461_bib255","doi-asserted-by":"crossref","first-page":"432","DOI":"10.37349\/etat.2024.00227","article-title":"Tri-specific killer engager: unleashing multi-synergic power against cancer","volume":"5","author":"Winidmanokul","year":"2024","journal-title":"Explor Target Antitumor Ther."},{"issue":"24","key":"10.1016\/j.ejphar.2026.179461_bib256","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2014-08-593269","article-title":"A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL","volume":"124","author":"Woyach","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejphar.2026.179461_bib258","doi-asserted-by":"crossref","first-page":"842","DOI":"10.7150\/thno.66575","article-title":"Fc\u03b3RIIB potentiates differentiation of myeloid-derived suppressor cells to mediate tumor immunoescape","volume":"12","author":"Wu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2026.179461_bib257","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114360","article-title":"The prospects for targeting FcR as a novel therapeutic strategy in rheumatoid arthritis","volume":"183","author":"Wu","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179461_bib260","article-title":"Inflammation mechanism and research progress of COPD. Review","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib259","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4049\/jimmunol.2000265","article-title":"Suppression of experimental autoimmune encephalomyelitis by ILT3. Fc","volume":"206","author":"Xu","year":"2021","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib261","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2026.2632421","article-title":"Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics","volume":"15","author":"Xue","year":"2026","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejphar.2026.179461_bib262","article-title":"From promise to practice: evaluating the clinical impact of FcRn inhibition in IgG-mediated autoimmune rheumatic diseases","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Immunol."},{"issue":"23","key":"10.1016\/j.ejphar.2026.179461_bib263","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314753","article-title":"Pathogenesis of \u03b1-Synuclein in parkinson's disease: from a Neuron-Glia Crosstalk Perspective","volume":"23","author":"Yi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib264","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48323-w","article-title":"The Fab portion of immunoglobulin G contributes to its binding to Fc\u03b3 receptor III","volume":"9","author":"Yogo","year":"2019","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179461_bib265","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejphar.2026.179461_bib266","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2019.02.016","article-title":"Current strategies in extending half-lives of therapeutic proteins","volume":"301","author":"Zaman","year":"2019","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib267","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2211185","article-title":"High concentration formulation developability approaches and considerations","volume":"15","author":"Zarzar","year":"2023","journal-title":"mAbs"},{"issue":"6","key":"10.1016\/j.ejphar.2026.179461_bib272","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","article-title":"Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection","volume":"23","author":"Zhang","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179461_bib268","article-title":"Fc\u03b3 receptor-mediated inflammation inhibits axon regeneration","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2026.179461_bib269","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.lfs.2018.06.015","article-title":"Fc\u03b3RI (CD64) contributes to the severity of immune inflammation through regulating NF-\u03baB\/NLRP3 inflammasome pathway","volume":"207","author":"Zhang","year":"2018","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179461_bib270","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98522","article-title":"NRG1-Fc improves metabolic health via dual hepatic and central action","volume":"3","author":"Zhang","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib271","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179461_bib273","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1021\/acs.jmedchem.1c01480","article-title":"Chemical synthesis of antibody\u2013hapten conjugates capable of recruiting the endogenous antibody to magnify the Fc effector immunity of antibody for cancer immunotherapy","volume":"65","author":"Zhou","year":"2021","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179461_bib274","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","article-title":"Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species","volume":"50","author":"Zilionis","year":"2019","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179461_bib275","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cmet.2017.02.006","article-title":"The role of the immune system in metabolic health and disease","volume":"25","author":"Zmora","year":"2017","journal-title":"Cell Metab."},{"issue":"10","key":"10.1016\/j.ejphar.2026.179461_bib276","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor\u2013targeting biologics for autoimmune diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejphar.2026.179461_bib277","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.688201","article-title":"Fc Gamma receptors as regulators of bone destruction in inflammatory arthritis. Systematic review","volume":"12","author":"Zuo","year":"2021","journal-title":"Front. Immunol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992600943X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992600943X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:23:31Z","timestamp":1793971411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992600943X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":276,"alternative-id":["S001429992600943X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179461","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological targeting of Fc receptor and FcRn pathways: Therapeutic antibody engineering in immune-mediated disorders","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179461"}}